Evidence map›Paper›PMID 35285705›Full record

ArticleMicrobiology spectrum2022

Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay.

Oran Erster, Ella Mendelson, Areej Kabat, Virginia Levy, Batya Mannasse, Hadar Assraf, Roberto Azar, Yaniv Ali, Efrat Bucris, Dana Bar-Ilan and 7 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Oran ErsterCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.ORCID 0000-0003-4839-8997
Ella MendelsonCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Areej KabatCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Virginia LevyCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Batya MannasseCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Hadar AssrafCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Roberto AzarCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Yaniv AliCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Efrat BucrisCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Dana Bar-IlanCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Orna MorCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Michal ElulCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Michal MandelboimCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Danit SoferCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Shay FleishonCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Neta S Zuckerman *Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.
Itay Bar-Or *Central Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Centergrid.413795.d, Ramat Gan, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this report, we describe the development of a reverse transcription-quantitative PCR (RT-qPCR) assay, termed Alpha-Delta assay, which can detect all severe acute respiratory syndrome coronavirus 2 (SC-2) variants and distinguish between the Alpha (B.1.1.7) and Delta (B.1.617.2) variants. The Alpha- and Delta-specific reactions in the assay target mutations that are strongly linked to the target variant. The Alpha reaction targets the D3L substitution in the N gene, and the Delta reaction targets the spike gene 156 to 158 mutations. Additionally, we describe a second Delta-specific assay that we use as a confirmatory test for the Alpha-Delta assay that targets the 119 to 120 deletion in the Orf8 gene. Both reactions have similar sensitivities of 15 to 25 copies per reaction, similar to the sensitivity of commercial SC-2 detection tests. The Alpha-Delta assay and the Orf8

Indexed as

COVID-19SARS-CoV-2HumansReal-Time Polymerase Chain ReactionWhole Genome SequencingAlpha (B.1.1.7)classificationDelta (B.1.617.2)diagnostic assayRT-qPCRSARS-COV-2SC-2 surveillance

Identifiers

PMID35285705
PMCPMC9045307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.